GlassScriptPhysician profile
Suzanne H Grantham
NPI 1427039098
$31,138.81
in general payments reported to CMS, 2019-2025
35 companies · $6,118 in 2025
The $6,118 reported for 2025 was more than what 99% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $5,902 · 2022: $4,875 · 2023: $9,203 · 2024: $5,042 · 2025: $6,118.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $9,488 · Travel and Lodging: $657 · Education: $8.58.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,209.36 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $9,487.50 |
| Travel and Lodging | $656.85 |
| Education | $8.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $17,565.40 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $1,827.68 | 2021-2025 | Rexulti, Nuedexta, Abilify Maintena |
| Alkermes, INC. | $1,592.32 | 2021-2025 | Aristada, Lybalvi, Aristada Initio |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,540.74 | 2021-2025 | Caplyta |
| Lundbeck LLC | $1,061.88 | 2021-2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $959.08 | 2021-2025 | Trintellix |
| Bausch Health US, LLC | $950.22 | 2021-2025 | Aplenzin, Wellbutrin |
| Corium, LLC | $724.41 | 2021-2025 | Azstarys |
| Neurocrine Biosciences, INC. | $713.41 | 2021-2025 | Ingrezza |
| Axsome Therapeutics, INC. | $593.72 | 2022-2025 | Auvelity |
| Janssen Pharmaceuticals, INC | $534.41 | 2021-2025 | Spravato |
| Vanda Pharmaceuticals INC. | $489.13 | 2021-2025 | Fanapt |
| Sunovion Pharmaceuticals INC. | $438.50 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $394.70 | 2022-2025 | Austedo Xr, Austedo Xr, Austedo |
| Tris Pharma INC | $383.20 | 2023-2024 | Dyanavel Xr |
Show all 35 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Suzanne Grantham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.